The CTC has been running trials in gastrointestinal cancers since 1982 and has expertise in treatment trials for rectal, anal, colorectal, liver and biliary tract cancers. These trials have involved many different types of treatment including radiotherapy, transarterial chemoembolisation (TACE), photodynamic therapy (PDT) as well as chemotherapy. Two of the largest treatment trials in anal cancer ever conducted were run by the CTC. ACT I and ACT II have now both closed to recruitment but follow up continues. Preliminary data from ACT II was presented at ASCO 2009 and the main analysis is now underway.
Positive results from ABC-02, the largest randomised phase III trial in biliary tract cancer, were published in the New England Journal of Medicine (N Engl J Med 2010; 362:1273-1281April 8, 2010) and have defined cisplatin + gemcitabine as standard treatment for this rare cancer. The success of this trial has led to the follow on trials which are currently open and recruiting- the ABC-03 and ABC-04 trials